APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurological Biomarkers

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

Selected research

Market Outlook & Growth Opportunities

Global Neurological Biomarkers Market Outlook and Growth Opportunities 2026

21 December 2025206 pages

Choose your research edition.

Industry ResearchNeurological Biomarkers Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurological Biomarkers Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Neurological Biomarkers Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurological Biomarkers Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurological Biomarkers Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

Global Neurological Biomarkers key players include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, etc. Global top four manufacturers hold a share about 25%.

North America is the largest market, with a share over 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.

Read the full market overview

In terms of product, Proteomics is the largest segment, with a share about 30%. And in terms of application, the largest application is Proteomics, followed by Drug Discovery, Personalized Medicine, etc.

This report provides an overview of the global Neurological Biomarkers market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurological Biomarkers and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurological Biomarkers sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurological Biomarkers market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurological Biomarkers Segment by Company

Thermo Fisher Scientific

Merck

Quest Diagnostics

Abbott

Roche

Illumina

Bio-Rad Laboratories

QIAGEN

Myriad RBM

Cisbio Bioassays

Athena Diagnostics

BGI

Wuxi APP

Aepodia

Proteome Sciences

Genewiz

Neurological Biomarkers Segment by Type

Proteomics

Genomics

Imaging

Bioinformatics

Others

Neurological Biomarkers Segment by Application

Diagnostics

Drug Discovery

Personalized Medicine

Others

Neurological Biomarkers Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neurological Biomarkers status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neurological Biomarkers market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurological Biomarkers significant trends, drivers, influence factors in global and regions.

6. To analyze Neurological Biomarkers competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurological Biomarkers market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurological Biomarkers and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurological Biomarkers.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurological Biomarkers market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurological Biomarkers industry.

Chapter 3: Detailed analysis of Neurological Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neurological Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neurological Biomarkers in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurological Biomarkers Industry Trends Table 2. Neurological Biomarkers Industry Drivers Table 3. Neurological Biomarkers Industry Opportunities and Challenges Table 4. Neurological Biomarkers Industry Restraints Table 5. Global Neurological Biomarkers Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurological Biomarkers Revenue Share by Company (2021-2026) Table 7. Global Neurological Biomarkers Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Neurological Biomarkers Sales Volume Share by Company (2021-2026) Table 9. Global Neurological Biomarkers Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Neurological Biomarkers Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neurological Biomarkers Key Company Manufacturing Base & Headquarters Table 12. Global Neurological Biomarkers Company, Product Type & Application Table 13. Global Neurological Biomarkers Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurological Biomarkers by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Proteomics Table 18. Significant Companies of Genomics Table 19. Significant Companies of Imaging Table 20. Significant Companies of Bioinformatics Table 21. Significant Companies of Others Table 22. Global Neurological Biomarkers Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Neurological Biomarkers Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Neurological Biomarkers Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Neurological Biomarkers Sales Volume Share by Type (2021-2026) Table 26. Global Neurological Biomarkers Sales Volume Share by Type (2027-2032) Table 27. Global Neurological Biomarkers Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neurological Biomarkers Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Neurological Biomarkers Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Neurological Biomarkers Sales Value Share by Type (2021-2026) Table 31. Global Neurological Biomarkers Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Diagnostics Table 33. Significant Companies of Drug Discovery Table 34. Significant Companies of Personalized Medicine Table 35. Significant Companies of Others Table 36. Global Neurological Biomarkers Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Neurological Biomarkers Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Neurological Biomarkers Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Neurological Biomarkers Sales Volume Share by Application (2021-2026) Table 40. Global Neurological Biomarkers Sales Volume Share by Application (2027-2032) Table 41. Global Neurological Biomarkers Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Neurological Biomarkers Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Neurological Biomarkers Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Neurological Biomarkers Sales Value Share by Application (2021-2026) Table 45. Global Neurological Biomarkers Sales Value Share by Application (2027-2032) Table 46. Global Neurological Biomarkers Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Neurological Biomarkers Sales by Region (2021-2026) & (K Units) Table 48. Global Neurological Biomarkers Sales Market Share by Region (2021-2026) Table 49. Global Neurological Biomarkers Sales by Region (2027-2032) & (K Units) Table 50. Global Neurological Biomarkers Sales Market Share by Region (2027-2032) Table 51. Global Neurological Biomarkers Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Neurological Biomarkers Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Neurological Biomarkers Sales Value Share by Region (2021-2026) Table 54. Global Neurological Biomarkers Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Neurological Biomarkers Sales Value Share by Region (2027-2032) Table 56. Global Neurological Biomarkers Market Average Price (USD/Unit) by Region (2021-2026) Table 57. Global Neurological Biomarkers Market Average Price (USD/Unit) by Region (2027-2032) Table 58. Global Neurological Biomarkers Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Neurological Biomarkers Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Neurological Biomarkers Sales by Country (2021-2026) & (K Units) Table 61. Global Neurological Biomarkers Sales Market Share by Country (2021-2026) Table 62. Global Neurological Biomarkers Sales by Country (2027-2032) & (K Units) Table 63. Global Neurological Biomarkers Sales Market Share by Country (2027-2032) Table 64. Global Neurological Biomarkers Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Neurological Biomarkers Sales Value Market Share by Country (2021-2026) Table 66. Global Neurological Biomarkers Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Neurological Biomarkers Sales Value Market Share by Country (2027-2032) Table 68. Thermo Fisher Scientific Company Information Table 69. Thermo Fisher Scientific Business Overview Table 70. Thermo Fisher Scientific Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 71. Thermo Fisher Scientific Neurological Biomarkers Product Portfolio Table 72. Thermo Fisher Scientific Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. Merck Neurological Biomarkers Product Portfolio Table 77. Merck Recent Development Table 78. Quest Diagnostics Company Information Table 79. Quest Diagnostics Business Overview Table 80. Quest Diagnostics Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 81. Quest Diagnostics Neurological Biomarkers Product Portfolio Table 82. Quest Diagnostics Recent Development Table 83. Abbott Company Information Table 84. Abbott Business Overview Table 85. Abbott Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 86. Abbott Neurological Biomarkers Product Portfolio Table 87. Abbott Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Roche Neurological Biomarkers Product Portfolio Table 92. Roche Recent Development Table 93. Illumina Company Information Table 94. Illumina Business Overview Table 95. Illumina Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Illumina Neurological Biomarkers Product Portfolio Table 97. Illumina Recent Development Table 98. Bio-Rad Laboratories Company Information Table 99. Bio-Rad Laboratories Business Overview Table 100. Bio-Rad Laboratories Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. Bio-Rad Laboratories Neurological Biomarkers Product Portfolio Table 102. Bio-Rad Laboratories Recent Development Table 103. QIAGEN Company Information Table 104. QIAGEN Business Overview Table 105. QIAGEN Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. QIAGEN Neurological Biomarkers Product Portfolio Table 107. QIAGEN Recent Development Table 108. Myriad RBM Company Information Table 109. Myriad RBM Business Overview Table 110. Myriad RBM Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Myriad RBM Neurological Biomarkers Product Portfolio Table 112. Myriad RBM Recent Development Table 113. Cisbio Bioassays Company Information Table 114. Cisbio Bioassays Business Overview Table 115. Cisbio Bioassays Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. Cisbio Bioassays Neurological Biomarkers Product Portfolio Table 117. Cisbio Bioassays Recent Development Table 118. Athena Diagnostics Company Information Table 119. Athena Diagnostics Business Overview Table 120. Athena Diagnostics Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. Athena Diagnostics Neurological Biomarkers Product Portfolio Table 122. Athena Diagnostics Recent Development Table 123. BGI Company Information Table 124. BGI Business Overview Table 125. BGI Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 126. BGI Neurological Biomarkers Product Portfolio Table 127. BGI Recent Development Table 128. Wuxi APP Company Information Table 129. Wuxi APP Business Overview Table 130. Wuxi APP Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 131. Wuxi APP Neurological Biomarkers Product Portfolio Table 132. Wuxi APP Recent Development Table 133. Aepodia Company Information Table 134. Aepodia Business Overview Table 135. Aepodia Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 136. Aepodia Neurological Biomarkers Product Portfolio Table 137. Aepodia Recent Development Table 138. Proteome Sciences Company Information Table 139. Proteome Sciences Business Overview Table 140. Proteome Sciences Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 141. Proteome Sciences Neurological Biomarkers Product Portfolio Table 142. Proteome Sciences Recent Development Table 143. Genewiz Company Information Table 144. Genewiz Business Overview Table 145. Genewiz Neurological Biomarkers Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 146. Genewiz Neurological Biomarkers Product Portfolio Table 147. Genewiz Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Neurological Biomarkers Distributors List Table 151. Neurological Biomarkers Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Neurological Biomarkers Product Image Figure 2. Global Neurological Biomarkers Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurological Biomarkers Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neurological Biomarkers Sales (2021-2032) & (K Units) Figure 5. Global Neurological Biomarkers Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Neurological Biomarkers Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Proteomics Image Figure 10. Genomics Image Figure 11. Imaging Image Figure 12. Bioinformatics Image Figure 13. Others Image Figure 14. Global Neurological Biomarkers Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Neurological Biomarkers Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Neurological Biomarkers Sales Volume Share by Type (2021-2032) Figure 17. Global Neurological Biomarkers Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Neurological Biomarkers Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Neurological Biomarkers Sales Value Share by Type (2021-2032) Figure 20. Diagnostics Image Figure 21. Drug Discovery Image Figure 22. Personalized Medicine Image Figure 23. Others Image Figure 24. Global Neurological Biomarkers Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Neurological Biomarkers Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Neurological Biomarkers Sales Volume Share by Application (2021-2032) Figure 27. Global Neurological Biomarkers Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Neurological Biomarkers Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Neurological Biomarkers Sales Value Share by Application (2021-2032) Figure 30. Global Neurological Biomarkers Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Neurological Biomarkers Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Neurological Biomarkers Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Neurological Biomarkers Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Neurological Biomarkers Sales Value (2021-2032) & (US$ Million) Figure 35. North America Neurological Biomarkers Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Neurological Biomarkers Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Neurological Biomarkers Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Neurological Biomarkers Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Neurological Biomarkers Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Neurological Biomarkers Sales Value (2021-2032) & (US$ Million) Figure 41. South America Neurological Biomarkers Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Neurological Biomarkers Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Neurological Biomarkers Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Neurological Biomarkers Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Neurological Biomarkers Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Neurological Biomarkers Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Proteomics
  • Genomics
  • Imaging
  • Bioinformatics
  • Others
Applications
  • Diagnostics
  • Drug Discovery
  • Personalized Medicine
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • Quest Diagnostics
  • Abbott
  • Roche
  • Illumina
  • Bio-Rad Laboratories
  • QIAGEN
  • Myriad RBM
  • Cisbio Bioassays
  • Athena Diagnostics
  • BGI
  • Wuxi APP
  • Aepodia
  • Proteome Sciences
  • Genewiz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurological Biomarkers Sales Value (2021-2032)
  4. 1.2.2 Global Neurological Biomarkers Sales Volume (2021-2032)
  5. 1.2.3 Global Neurological Biomarkers Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neurological Biomarkers Market Dynamics
  1. 2.1 Neurological Biomarkers Industry Trends
  2. 2.2 Neurological Biomarkers Industry Drivers
  3. 2.3 Neurological Biomarkers Industry Opportunities and Challenges
  4. 2.4 Neurological Biomarkers Industry Restraints
3 Neurological Biomarkers Market by Company
  1. 3.1 Global Neurological Biomarkers Company Revenue Ranking in 2025
  2. 3.2 Global Neurological Biomarkers Revenue by Company (2021-2026)
  3. 3.3 Global Neurological Biomarkers Sales Volume by Company (2021-2026)
  4. 3.4 Global Neurological Biomarkers Average Price by Company (2021-2026)
  5. 3.5 Global Neurological Biomarkers Company Ranking (2024-2026)
  6. 3.6 Global Neurological Biomarkers Company Manufacturing Base and Headquarters
  7. 3.7 Global Neurological Biomarkers Company Product Type and Application
  8. 3.8 Global Neurological Biomarkers Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neurological Biomarkers Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neurological Biomarkers Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neurological Biomarkers Market by Type
  1. 4.1 Neurological Biomarkers Type Introduction
  2. 4.1.1 Proteomics
  3. 4.1.2 Genomics
  4. 4.1.3 Imaging
  5. 4.1.4 Bioinformatics
  6. 4.1.5 Others
  7. 4.2 Global Neurological Biomarkers Sales Volume by Type
  8. 4.2.1 Global Neurological Biomarkers Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Neurological Biomarkers Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Neurological Biomarkers Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Neurological Biomarkers Sales Value by Type
  12. 4.3.1 Global Neurological Biomarkers Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Neurological Biomarkers Sales Value by Type (2021-2032)
  14. 4.3.3 Global Neurological Biomarkers Sales Value Share by Type (2021-2032)
5 Neurological Biomarkers Market by Application
  1. 5.1 Neurological Biomarkers Application Introduction
  2. 5.1.1 Diagnostics
  3. 5.1.2 Drug Discovery
  4. 5.1.3 Personalized Medicine
  5. 5.1.4 Others
  6. 5.2 Global Neurological Biomarkers Sales Volume by Application
  7. 5.2.1 Global Neurological Biomarkers Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurological Biomarkers Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neurological Biomarkers Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neurological Biomarkers Sales Value by Application
  11. 5.3.1 Global Neurological Biomarkers Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neurological Biomarkers Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neurological Biomarkers Sales Value Share by Application (2021-2032)
6 Neurological Biomarkers Regional Sales and Value Analysis
  1. 6.1 Global Neurological Biomarkers Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurological Biomarkers Sales by Region (2021-2032)
  3. 6.2.1 Global Neurological Biomarkers Sales by Region: 2021-2026
  4. 6.2.2 Global Neurological Biomarkers Sales by Region (2027-2032)
  5. 6.3 Global Neurological Biomarkers Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neurological Biomarkers Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neurological Biomarkers Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neurological Biomarkers Sales Value by Region (2027-2032)
  9. 6.5 Global Neurological Biomarkers Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neurological Biomarkers Sales Value (2021-2032)
  12. 6.6.2 North America Neurological Biomarkers Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neurological Biomarkers Sales Value (2021-2032)
  15. 6.7.2 Europe Neurological Biomarkers Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neurological Biomarkers Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neurological Biomarkers Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neurological Biomarkers Sales Value (2021-2032)
  21. 6.9.2 South America Neurological Biomarkers Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neurological Biomarkers Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neurological Biomarkers Sales Value Share by Country, 2025 VS 2032
7 Neurological Biomarkers Country-level Sales and Value Analysis
  1. 7.1 Global Neurological Biomarkers Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurological Biomarkers Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neurological Biomarkers Sales by Country (2021-2032)
  4. 7.3.1 Global Neurological Biomarkers Sales by Country (2021-2026)
  5. 7.3.2 Global Neurological Biomarkers Sales by Country (2027-2032)
  6. 7.4 Global Neurological Biomarkers Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neurological Biomarkers Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neurological Biomarkers Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neurological Biomarkers Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neurological Biomarkers Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neurological Biomarkers Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Neurological Biomarkers Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Quest Diagnostics
  14. 8.3.1 Quest Diagnostics Company Information
  15. 8.3.2 Quest Diagnostics Business Overview
  16. 8.3.3 Quest Diagnostics Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
  18. 8.3.5 Quest Diagnostics Recent Developments
  19. 8.4 Abbott
  20. 8.4.1 Abbott Company Information
  21. 8.4.2 Abbott Business Overview
  22. 8.4.3 Abbott Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Abbott Neurological Biomarkers Product Portfolio
  24. 8.4.5 Abbott Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Neurological Biomarkers Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Illumina
  32. 8.6.1 Illumina Company Information
  33. 8.6.2 Illumina Business Overview
  34. 8.6.3 Illumina Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Illumina Neurological Biomarkers Product Portfolio
  36. 8.6.5 Illumina Recent Developments
  37. 8.7 Bio-Rad Laboratories
  38. 8.7.1 Bio-Rad Laboratories Company Information
  39. 8.7.2 Bio-Rad Laboratories Business Overview
  40. 8.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
  42. 8.7.5 Bio-Rad Laboratories Recent Developments
  43. 8.8 QIAGEN
  44. 8.8.1 QIAGEN Company Information
  45. 8.8.2 QIAGEN Business Overview
  46. 8.8.3 QIAGEN Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 QIAGEN Neurological Biomarkers Product Portfolio
  48. 8.8.5 QIAGEN Recent Developments
  49. 8.9 Myriad RBM
  50. 8.9.1 Myriad RBM Company Information
  51. 8.9.2 Myriad RBM Business Overview
  52. 8.9.3 Myriad RBM Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
  54. 8.9.5 Myriad RBM Recent Developments
  55. 8.10 Cisbio Bioassays
  56. 8.10.1 Cisbio Bioassays Company Information
  57. 8.10.2 Cisbio Bioassays Business Overview
  58. 8.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
  60. 8.10.5 Cisbio Bioassays Recent Developments
  61. 8.11 Athena Diagnostics
  62. 8.11.1 Athena Diagnostics Company Information
  63. 8.11.2 Athena Diagnostics Business Overview
  64. 8.11.3 Athena Diagnostics Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
  66. 8.11.5 Athena Diagnostics Recent Developments
  67. 8.12 BGI
  68. 8.12.1 BGI Company Information
  69. 8.12.2 BGI Business Overview
  70. 8.12.3 BGI Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 BGI Neurological Biomarkers Product Portfolio
  72. 8.12.5 BGI Recent Developments
  73. 8.13 Wuxi APP
  74. 8.13.1 Wuxi APP Company Information
  75. 8.13.2 Wuxi APP Business Overview
  76. 8.13.3 Wuxi APP Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
  78. 8.13.5 Wuxi APP Recent Developments
  79. 8.14 Aepodia
  80. 8.14.1 Aepodia Company Information
  81. 8.14.2 Aepodia Business Overview
  82. 8.14.3 Aepodia Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Aepodia Neurological Biomarkers Product Portfolio
  84. 8.14.5 Aepodia Recent Developments
  85. 8.15 Proteome Sciences
  86. 8.15.1 Proteome Sciences Company Information
  87. 8.15.2 Proteome Sciences Business Overview
  88. 8.15.3 Proteome Sciences Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
  90. 8.15.5 Proteome Sciences Recent Developments
  91. 8.16 Genewiz
  92. 8.16.1 Genewiz Company Information
  93. 8.16.2 Genewiz Business Overview
  94. 8.16.3 Genewiz Neurological Biomarkers Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Genewiz Neurological Biomarkers Product Portfolio
  96. 8.16.5 Genewiz Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurological Biomarkers Value Chain Analysis
  2. 9.1.1 Neurological Biomarkers Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurological Biomarkers Sales Mode & Process
  6. 9.2 Neurological Biomarkers Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurological Biomarkers Distributors
  9. 9.2.3 Neurological Biomarkers Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst